According to a new report, published by KBV research, The Global Metastatic Cancer Drugs Market size is expected to reach $115.6 billion by 2030, rising at a market growth of 7.2% CAGR during the forecast period.
The Online Providers segment would showcase a CAGR of 8.1% during (2023 - 2030). Patients who might prefer to acquire medications from their homes can find it convenient to buy cancer drugs online. Online sources can provide useful resources and information about medications for metastatic cancer. It saves time & energy by removing the need for physical visits to a pharmacy or treatment facility.
The Breast Cancer segment captured highest revenue in the Global Metastatic Cancer Drugs Market by Indication in 2022; thereby, achieving a market value of $37.2 billion by 2030. One of the most typical forms of cancer is breast cancer. Women experience it more frequently than males. The main risk factors for breast cancer are being overweight, living a sedentary lifestyle, getting older, having a genetic mutation, and being exposed to radiation.
The Immunotherapy segment would register a CAGR of 7.5% during (2023 - 2030). Immunotherapy is anticipated to show a growth trend throughout the projection period. In this market segment, only Provenge has FDA approval. It is the initial vaccine of its kind to prevent prostate cancer. With continuing gene therapy, stem cell treatment, small chemical, and vaccination trials, the pipeline for prostate cancer shows significant promise.
The North America region dominated the Global Metastatic Cancer Drugs Market by Region in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $54.2 billion by 2030. The Europe market is anticipated to grow at a CAGR of 6.7% during (2023 - 2030). Additionally, The Asia Pacific market would witness a CAGR of 8.3% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/metastatic-cancer-drugs-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bristol Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen, Inc. and Sanofi S.A.
By Distribution Channel
By Indication
By Therapy
By Geography
Companies Profiled
Unique Offerings 
